The Mysterious Origins of Sarcomas: Pathogenetic Factors in Soft Tissue and Bone Sarcomas

🔬 Sarcomas: Rare but Serious Cancers

Sarcomas arise from the body's connective tissues and are rare but aggressive tumors. Bones, muscles, fat, nerves and blood vessels are among the structures they can affect. Most originate in soft tissue , while others develop in bone .

Although uncommon, their tendency to spread rapidly and their challenging treatment make sarcomas important from both clinical and scientific perspectives .

🧬 Why Do They Develop?

Although most cases have no identifiable cause, many predisposing factors have been recognized:

• 🧬 Genetic predisposition and inherited syndromes
• 🧪 Somatic gene mutations
• ☢️ Previous radiation and chemotherapy
• 🌫️ Industrial chemical exposure
• 🦠 Chronic infection and irritation

This article explores sarcomas' complex biological origins to illuminate pathways toward better diagnosis, risk assessment and targeted treatment .

Some soft tissue and bone sarcoma patients, particularly children, carry inherited genetic risks. These may relate to recognized inherited syndromes (e.g., Li-Fraumeni) or genetic variations not yet named.

Next-generation sequencing studies show that approximately 50% of sarcoma patients have genetic mutations associated with cancer risk .

Li-Fraumeni syndrome (LFS), occurs in carriers of inherited TP53 mutations and predisposes to many cancers, including childhood sarcoma .

• Sarcoma types: Osteosarcoma, rhabdomyosarcoma, pleomorphic sarcoma, liposarcoma, leiomyosarcoma
• Other cancers: Breast cancer, brain tumors, leukemia, adrenal cortical tumors
• Mechanism: TP53 mutations render p53 protein nonfunctional, disrupting DNA repair and accelerating tumor development.

Familial adenomatous polyposis (FAP)is an inherited colorectal cancer syndrome. It also predisposes to intra-abdominal desmoid tumors , among other soft tissue lesions .

These tumors develop through APC gene mutations, and the syndrome is also called Gardner syndrome . Desmoid tumors generally do not metastasize but are locally aggressive .

Retinoblastoma (RB), particularly the hereditary form , increases later-life risk of osteosarcoma and other soft tissue sarcomas .

RB1 gene mutations increase this risk. In addition, radiotherapy may shorten the time to a second sarcoma and increase its risk.

NF1 syndrome, also known as Von Recklinghausen disease , results from NF1 gene mutations.

The gene encodes neurofibromin, which regulates cell proliferation by suppressing Ras signaling . Mutations remove this control, allowing malignant peripheral nerve sheath tumors (MPNST) to develop.

Rothmund-Thomson syndrome, is an autosomal recessive condition that increases osteosarcoma risk. This rare syndrome features skin pigmentation abnormalities, hair loss and skeletal anomalies.

Sarcoma genetics fall into two broad groups: specific genetic alterations (e.g., fusion genes or point mutations) and nonspecific genetic alterations (complex, unbalanced karyotypes). This distinction is critical for identifying treatment targets.

Some soft tissue sarcomas show recurrent chromosomal translocations . These create gene fusions and abnormal proteins contributing to tumor development and maintenance. These signatures matter for both definitive diagnosis and identifying treatment targets .

Of soft tissue sarcomas, approximately one third carry a specific translocation, while most others have complex karyotypes . As the number of genomic changes increases, the sarcoma's histological grade generally rises. This is associated with more aggressive tumor features and a worse prognosis .

Immunohistochemistry, cytogenetic analysis and next-generation sequencing (NGS) are critical for diagnosing and classifying soft tissue sarcomas. In particular, fusion gene testsoffer a genetically based approach to differential diagnosis.

In the near future, gene expression profiling and other advanced molecular techniques will predict disease course more clearly and enable patient-specific targeted treatments .

Radiotherapy (RT)is a known risk factor for soft tissue and bone sarcomas. The most common radiation-associated soft tissue type is undifferentiated pleomorphic sarcoma (UPS), while among bone sarcomas, osteosarcoma predominates. In women irradiated for breast cancer, the most common secondary sarcoma is cutaneous angiosarcoma.

Sarcoma risk varies with radiation dose, exposure duration and age , among other factors. Childhood cancer survivors face higher risk, particularly after both RT and anthracycline / alkylating-agent chemotherapy. Secondary sarcomas may behave worse than primary sarcomas, but aggressive treatment is warranted because they remain potentially treatable .

Although occupational epidemiology data are limited, associations between certain chemicals and sarcoma have been clearly demonstrated. Examples include:

• Vinyl chloride / Arsenic: → Hepatic angiosarcoma
• Phenoxy herbicides: → Possible association with soft tissue sarcoma
• Chlorophenol derivatives: (e.g., TCDD) → Higher sarcoma risk with high exposure

In particular, angiosarcomasmay develop after prolonged edema. The classic example is Stewart-Treves syndrome, developing in a lymphedematous arm after mastectomy.

Chronic foreign-body irritation and trauma have also been associated with desmoid tumors and other sarcomas. Beyond triggering symptoms, trauma has also been considered a trigger for tumor development in animal models .

Viral infections rarely contribute to sarcoma, but some examples are notable:

• HHV-8 (Human Herpesvirus 8): → In Kaposi sarcoma pathogenesis
• EBV (Epstein-Barr Virus): → Smooth muscle tumors in HIV/AIDS or immunosuppressed patients

Soft tissue and bone sarcomas arise through interactions among genetic predisposition, somatic mutations, chromosomal translocations, radiotherapy, chemotherapy, chemical exposure and chronic inflammation , among other factors, and are complex diseases.

Molecular genetic testsare increasingly important for classifying these rare tumors and guiding treatment. Personalized treatment options informed by this knowledge will become even more prominent.

Every science-guided step in addressing these rare cancers remains a source of hope for patients.